Prior to the creation of Preora, Dr. Vadim Backman’s Northwestern University laboratory had received close to $20 million in NIH and NSF grants for the development of the core PWS NanocytologyTM platform, and an additional $7 million in fast-track SBIR/STTR grants to support the product and process development for commercialization.

The extraordinarily high level of grant funding serves as evidence of the clinical potential of our technology platform.

The company has completed a $3.65 million SAFE round, and is currently seeking  financing through a Series A round. Preora is actively seeking commercial partnerships for the manufacture and distribution rights of its technologies.

Over the next three to five years, the company plans to license and/or sell its technologies to organizations that offer the best opportunity for adoption due to their regional or global commercialization capabilities and expertise.

Please contact John Hart, Preora Healthcare, president and CEO, at, or Micah Litow, chief marketing and business development officer,, to indicate interest or learn more about investment opportunities.

Recently Completed Milestones

  • Received NIH SBIR research grant for $1.5 million for ongoing lung cancer test clinical studies (Q3 2016)
  • Completed PWS Nanocytology microscope upgrades to improve efficiency and effectiveness (Q4 2016)
  • Completed multiple PWS Nanocytology microscope equivalency and repeatability studies (Q1 2017)
  • Obtained ISO 13485 Certification for product design, development and manufacturing (Q2 2017)
  • Received 2017 Northwestern University INVO N.XT investment award (Q2 2017)
  • Completed market research to validate commercialization opportunities of the sample preparation system (Q3 2017)
  • Finalist for 2017 Chicago Innovation Awards (Q3 2017)
  • Finalist for 2017 HealthTECH Startup Competition (Q4 2017)

Future Key Milestones

  • Finalize Requirements Definition for the sample prep system for the ROSE procedure and initiate product development (Q4 2017)
  • Finalize operating procedures for the lung test multisite clinical validation studies (Q4 2017)
  • Initiate pivotal clinical studies for the lung test (Q1 2018)
  • Complete Series A investment round and develop commercial partnerships for the sample preparation system and early-stage cancer screening tests (Q1 2018)

Important Notices & Disclaimer

This website has been prepared solely for informational purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell securities of Preora or any security or instrument or to participate in any trading strategy. No sale of securities will be made in any jurisdiction in which the offer, solicitation or sale is not authorized or to any person to whom it is unlawful to make the offer, solicitation or sale.  If any such offer of securities is made by Preora, it will be made pursuant to a definitive private placement memorandum (the “Memorandum”) prepared by Preora that contains material information not contained in this website and to which prospective investors will be referred. Any decision to invest in securities should be made solely in reliance upon the Memorandum.

No representation or warranty (express or implied) is made or can be given with respect to the accuracy or completeness of the information in this website, or that any offer of securities will conform to the terms described in this website. Certain assumptions have been made regarding the financial performance information included in this website, and such performance information is presented by way of example only. No representation is made that the performance presented will be achieved by Preora, or that every assumption made in achieving, calculating or presenting the financial performance information in this website has been considered or stated in preparing this website. Any changes to assumptions that may have been made in preparing the website could have a material impact on the investment returns that are included in this website by way of example.  Financial projections may not be indicative of future performance or investment returns, and prospective investors should not view the projections in this website as an indicator of the future performance of Preora. An investment in Preora is speculative and involves significant risks, including the risk of loss of the entire investment.  The risks include, but are not limited to the following: the uncertainty of the national economy; economic conditions generally and the healthcare market specifically.